Biomea Fusion, Inc. (NASDAQ:BMEA) Downgraded by Barclays

By Yahoo! Finance | Jun 11, 2024 at 11:40 AM EST

Analysts lowered ratings for various stocks, including Biomea Fusion, Inc. due to FDA's clinical hold on BMF-219 trials. Despite setbacks, some analysts remain optimistic about the company's long-term potential. The stock closed at $4.31 on June 10 amidst market volatility.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.